- Amendments to the Claims -

1. - 57. (Canceled)

58. (Currently amended) A method of treatment of a mammal, including a human being, to treat an inflammatory disease including treating said mammal with an effective amount of a compound of the formula (I)



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein

R^1 is H, C_1-C_6 alkyl or fluorenyl, said C_1-C_6 alkyl being optionally substituted by 1 or 2 substituents each independently selected from phenyl and naphthyl, said phenyl and naphthyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;

(A) R^2 is H or C_1-C_6 alkyl, R^{15} is H or C_1-C_6 alkyl, and X is either (i) unbranched C_2-C_3 alkylene optionally substituted by C_1-C_6 alkyl or C_3-C_8 cycloalkyl, or (ii) a group of the formula:

$$-(CH_2)_n - W - (CH_2)_p -$$

where W is C_5-C_7 cycloalkylene optionally substituted by C_1-C_6 alkyl, n is 0 or 1 and p is 0 or 1, or

(B) R^{15} is H or C_1-C_6 alkyl, and R^2 and X, taken together with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, or

(C) R^2 is H or C_1-C_6 alkyl, and R^{15} and X, taken together with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl;

either, R^3 and R^4, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C_1-C_6 alkyl or C_3-C_8 cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by $-NR^6R^7$,

or, R^3 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl and R^4 is

(a) azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl or het, or

(b) -(C_2-C_6 alkylene)-R^8,

(c) -(C_1-C_6 alkylene)-R^{13}, or

(d) C_1-C_6 alkyl or C_3-C_8 cycloalkyl;

R^5 is CH_2OH or $CONR^{14}R^{14}$;

R^6 and R^7 are either each independently H or C_1-C_6 alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl or

piperidinyl, said azetidinyl, pyrrolidinyl and piperidinyl being optionally substituted by C_1-C_6 alkyl;
R^8 is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, C_1-C_6 alkoxy-(C_1-C_6)-alkyl, R^9R^9N-(C_1-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^9$ or C_2-C_5 alkanoyl, and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1-C_6)-alkoxy, halo, $-OR^9$, cyano, $-S(O)_mR^{10}$, $-NR^9R^9$, $-SO_2NR^9R^9$, $-NR^9COR^{10}$ or $-NR^9SO_2R^{10}$, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C_2-C_6 alkylene group by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy-(C_2-C_6)-alkyl, R^9R^9N-(C_2-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, C_2-C_5 alkanoyl, $-COOR^{10}$, C_3-C_8 cycloalkyl, $-SO_2R^{10}$, $-SO_2NR^9R^9$ or $-CONR^9R^9$, or
(ii) $NR^{11}R^{12}$;
R^9 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;
R^{10} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;
R^{11} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl;
R^{12} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^{10}$, C_2-C_5 alkanoyl or $-SO_2NR^9R^9$;
R^{13} is (a) phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, -(C_1-C_3 alkylene)-(C_1-C_6 alkoxy), halo, cyano, -(C_1-C_3 alkylene)-CN, $-CO_2H$, -(C_1-C_3 alkylene)-CO_2H, $-CO_2$(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-CO_2(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-$NR^{14}R^{14}$, $-CONR^{14}R^{14}$ or -(C_1-C_3 alkylene)-$CONR^{14}R^{14}$, or (b) azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-2-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl or het;
R^{14} is H or C_1-C_6 alkyl optionally substituted by cyclopropyl;
m is 0, 1 or 2;
Y is CO, CS, SO_2 or C=N(CN); and
"het", used in the definition of R^4 and R^{13}, is a C-linked, 4- to 6-membered ring, heterocycle having either from 1 to 4 ring nitrogen heteroatoms or 1 or 2 nitrogen ring heteroatoms and 1 oxygen or 1 sulphur ring heteroatom, optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, hydroxy, oxo or halo ~~or with a pharmaceutically acceptable salt, solvate or composition thereof, as claimed in any one of claims 1 to 44 and 45 respectively~~.

59. (Canceled)

60. (Canceled)

61. (Original) A method of treatment of a mammal, including a human being, to treat septic shock, male erectile dysfunction, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischaemia, peripheral vascular disease, post-ischaemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic dermatitis, eczema, ulcerative colitis, Crohns disease, inflammatory bowel disease, *Heliobacter pylori* gastritis, non-*Heliobacter pylori* gastritis, non-steroidal anti-inflammatory drug-induced damage to the gastro-intestinal tract or a psychotic disorder, or for wound healing, including treating said mammal with an effective amount of a compound of the formula (I)



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein
R^1 is H, C_1-C_6 alkyl or fluorenyl, said C_1-C_6 alkyl being optionally substituted by 1 or 2 substituents each independently selected from phenyl and naphthyl, said phenyl and naphthyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;
(A) R^2 is H or C_1-C_6 alkyl, R^{15} is H or C_1-C_6 alkyl, and X is either (i) unbranched C_2-C_3 alkylene optionally substituted by C_1-C_6 alkyl or C_3-C_8 cycloalkyl, or (ii) a group of the formula:
$-(CH_2)_n-$ W - $(CH_2)_p$-

where W is C_5-C_7 cycloalkylene optionally substituted by C_1-C_6 alkyl, n is 0 or 1 and p is 0 or 1, or
(B) R^{15} is H or C_1-C_6 alkyl, and R^2 and X, taken together with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, or
(C) R^2 is H or C_1-C_6 alkyl, and R^{15} and X, taken together with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl;
either, R^3 and R^4, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C_1-C_6 alkyl or C_3-C_8 cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by $-NR^6R^7$,
or, R^3 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl and R^4 is
(a) azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl or het, or
(b) -(C_2-C_6 alkylene)-R^8,
(c) -(C_1-C_6 alkylene)-R^{13}, or
(d) C_1-C_6 alkyl or C_3-C_8 cycloalkyl;
R^5 is CH_2OH or $CONR^{14}R^{14}$;
R^6 and R^7 are either each independently H or C_1-C_6 alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl or piperidinyl, said azetidinyl, pyrrolidinyl and piperidinyl being optionally substituted by C_1-C_6 alkyl;
R^8 is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, C_1-C_6 alkoxy-(C_1-C_6)-alkyl, R^9R^9N-(C_1-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^9$ or C_2-C_5 alkanoyl, and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1-C_6)-alkoxy, halo, $-OR^9$, cyano, $-S(O)_mR^{10}$,

$-NR^9R^9$, $-SO_2NR^9R^9$, $-NR^9COR^{10}$ or $-NR^9SO_2R^{10}$, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C_2-C_6 alkylene group by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy-(C_2-C_6)-alkyl, R^9R^9N-(C_2-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, C_2-C_5 alkanoyl, $-COOR^{10}$, C_3-C_8 cycloalkyl, $-SO_2R^{10}$, $-SO_2NR^9R^9$ or $-CONR^9R^9$, or

(ii) $NR^{11}R^{12}$;

R^9 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{10} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{11} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl;

R^{12} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^{10}$, C_2-C_5 alkanoyl or $-SO_2NR^9R^9$;

R^{13} is (a) phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, -(C_1-C_3 alkylene)-(C_1-C_6 alkoxy), halo, cyano, -(C_1-C_3 alkylene)-CN, $-CO_2H$, -(C_1-C_3 alkylene)-CO_2H, $-CO_2$(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-CO_2(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-$NR^{14}R^{14}$, $-CONR^{14}R^{14}$ or -(C_1-C_3 alkylene)-$CONR^{14}R^{14}$, or (b) azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-2-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl or het;

R^{14} is H or C_1-C_6 alkyl optionally substituted by cyclopropyl;

m is 0, 1 or 2;

Y is CO, CS, SO_2 or C=N(CN); and

"het", used in the definition of R^4 and R^{13}, is a C-linked, 4- to 6-membered ring, heterocycle having either from 1 to 4 ring nitrogen heteroatoms or 1 or 2 nitrogen ring heteroatoms and 1 oxygen or 1 sulphur ring heteroatom, optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, hydroxy, oxo or halo ~~or with a pharmaceutically acceptable salt, solvate or composition thereof, as claimed in any one of claims 1 to 44 and 45 respectively~~.

62. - 77. (Canceled)

An early and favorable action is respectfully requested.

Respectfully submitted,

Dated: October 1, 2003

Robert T. Ronau
Attorney for Applicants
Reg. No. 36,257

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-5910